NL-OMON32184已完成3 期
A Phase III, randomized, double-blind study of TMC278 75 mg q.d. versus efavirenz 600 mg q.d. in combination with a fixed background regimen consisting of tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naïve HIV-1 infected subjects. - SPRINT : Simplified Pill Regimen In Naive patients with TMC278
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Male or female subjects, aged 18 years or older;
- •Subject with documented HIV-1 infection;
- •Subject has never been treated with a therapeutic HIV vaccine or an ARV drug prior to screening;
- •HIV-1 plasma viral load at screening is >= 5,000 HIV-1 RNA copies/mL
排除标准
- •Any previous treatment with a therapeutic HIV vaccine or use of ARVs, including use of NVP for the prevention of vertical HIV transmission;
- •Having documented genotypic evidence of NNRTI resistance at screening;
- •Previously documented HIV-2 infection;
- •Subject has any currently active AIDS defining illness (with a few exceptions).
研究者
相似试验
进行中（未招募）
不适用
A Phase III, randomized, double-blind trial of TMC278 25 mg q.d. versus efavirenz 600 mg q.d. in combination with a fixed background regimen consisting of tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naïve HIV-1 infected subjects - ECHOHIV infectionMedDRA version: 9.1Level: LLTClassification code 10020161Term: HIV infectionEUCTR2007-002646-38-SETibotec Pharmaceuticals680
进行中（未招募）
1 期
A Phase III, randomized, double-blind trial of TMC278 25 mg q.d. versus efavirenz 600 mg q.d. in combination with a fixed background regimen consisting of tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naïve HIV-1 infected subjects - ECHOHIV infectionMedDRA version: 9.1Level: LLTClassification code 10020161Term: HIV infectionEUCTR2007-002646-38-DKTibotec Pharmaceuticals
进行中（未招募）
不适用
A Phase III, randomized, double-blind trial of TMC278 25 mg q.d. versus efavirenz 600 mg q.d. in combination with a background regimen containing 2 nucleoside/nucleotide reverse transcriptase inhibitors in antiretroviral-naïve HIV-1 infected subjects - THRIVEEUCTR2007-002647-25-DETibotec Pharmaceuticals680
进行中（未招募）
不适用
A Phase III, randomized, double-blind trial of TMC278 25 mg q.d. versus efavirenz 600 mg q.d. in combination with a fixed background regimen consisting of tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naïve HIV-1 infected subjects - ECHOEUCTR2007-002646-38-ITTIBOTEC PHARMACEUTICALS LTD.680
进行中（未招募）
不适用
A Phase III, randomized, double-blind trial of TMC278 25 mg q.d. versus efavirenz 600 mg q.d. in combination with a background regimen containing 2 nucleoside/nucleotide reverse transcriptase inhibitors in antiretroviral-naïve HIV-1 infected subjectsHIV infectionMedDRA version: 9.1Level: LLTClassification code 10020161Term: HIV infectionEUCTR2007-002647-25-PTTibotec Pharmaceuticals680